No abstract

The current research has centered on the use of pharmacological and binding affinity methods to test the 36 compounds as bioactive constituents’ inhibitors for COVID-19. Six compounds out of 36 phytoconstituents (rutin, quercetin, catechin gallate, rhamnetin, campesterol and stigmasterol) have demonstrated outstanding molecular docking and drug-like properties as HIV inhibitors Lopinavir and Indinavir. Interestingly, the lowest binding energies (LBE) and the inhibition constant ( K i ) have showed that these compounds are able to bind to the P-glycoprotein substrate of 3CL pro and Nsp15. Interestingly, rutin has been found to be an excellent potential inhibitor for COVID-19 proteins because it has the best LBE score and K i value than those of other compounds, and of its ability to form strong H-bonds with COVID-19 proteins. The compounds that come next to the rutin compound are stigmasterol and campesterol. As a result, these compounds are considered possible novel inhibitors of COVID-19. In order to validate the computational results, more in vitro and in vivo investigations are required to support the findings of this research.

No abstract

No abstract

Dried aerial parts of three medicinal plants grown wild in Jordan, namely Ononis natrix L., Salvia spinosa L. and Salvia verbenace L., were extracted upon soaking with ethyl acetate by continuous shaking at room temperature for three days. The extracts were analyzed for their phenolic and flavonoids content by HPLC-PDA. The HPLC analysis of the plant extracts revealed the presence of flavonoids and phenolic compounds in the three plant extracts. The antibacterial activity of the crude extract was evaluated. The PDA wavelengths range was from 227-347 nm. Bioactivities were attributed mainly to the immense content of phenol-based compounds in plants.

Cancer continues to be leading cause of death globally, with nearly 7 million deaths per year. Despite significant progress in cancer research and treatment, there remain several challenges to overcome, including drug resistance, the presence of cancer stem cells, and high interstitial fluid pressure in tumors. To tackle these challenges, targeted therapy, specifically targeting HER2 (Human Epidermal Growth Factor Receptor 2) as well as EGFR (Epidermal Growth Factor Receptor), is considered a promising approach in cancer treatment. In recent years, phytocompounds have gained recognition as a potential source of chemopreventive and chemotherapeutic agents in tumor cancer treatment. Phytocompounds are compounds derived from medicinal plants that have the potential to treat and prevent cancer. This study aimed to investigate phytocompounds from Prunus amygdalus var amara seeds as inhibitors against EGFR and HER2 enzymes using in silico methods. In this study, fourteen phytocompounds were isolated from Prunus amygdalus var amara seeds and subjected to molecular docking studies to determine their ability to bind to EGFR and HER2 enzymes. The results showed that diosgenin and monohydroxy spirostanol exhibited binding energies comparable to those of the reference drugs, tak-285, and lapatinib. Furthermore, the drug-likeness and ADMET predictions, performed using the admetSAR 2.0 web-server tool, suggested that diosgenin and monohydroxy spirostanol have similar safety and ADMET properties as the reference drugs. To get deeper insight into the structural steadiness and flexibility of the complexes formed between these compounds and theEGFR and HER2 proteins, molecular dynamics simulations were performed for 100 ns. The results showed that the hit phytocompounds did not significantly affect the stability of the EGFR and HER2 proteins and were able to form stable interactions with the catalytic binding sites of the proteins. Additionally, the MM-PBSA analysis revealed that the binding free energy estimates for diosgenin and monohydroxy spirostanol is comparable to the reference drug, lapatinib. This study provides evidence that diosgenin and monohydroxy spirostanol may have the potential to act as dual suppressors of EGFR and HER2. Additional in vivo and in vitro research are needed to certify these results and assess their efficacy and safety as cancer therapy agents. The experimental data reported and these results are in agreement.

No abstract

Three medicinal plants grown wild in Jordan, namely Achillea santolina L, Achillea fragrantisimma, Asteriscus graveolens (Forssk) Less, were extracted with ethyl acetate by continuous shaking at room temperature for three days. The antibacterial activity of the crude extract was evaluated. The extracts were analyzed for their phenolic and flavonoids content by HPLC-PDA. The HPLC analysis of the plant extracts revealed the presence of flavonoids and phenolic compounds in the three plant extracts. Results revealed a strong antibacterial activity of A. graveolens against three bacterial strains (B. subtilis, E. coli, and S.aureus) while A. fragrantissima inhibited the growth of B. subtilis. Bioactivities were attributed mainly to the immense content of phenol-based compounds in plants.